141 related articles for article (PubMed ID: 29303931)
21. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
22. [Uterine Carcinosarcoma: Clinicopathological Features and Prognostic Factors].
Luz R; Ferreira J; Rocha M; Jorge AF; Félix A
Acta Med Port; 2016 Oct; 29(10):621-628. PubMed ID: 28103458
[TBL] [Abstract][Full Text] [Related]
23. Omental metastases in clinical stage I endometrioid adenocarcinoma.
Fujiwara H; Saga Y; Takahashi K; Ohwada M; Enomoto A; Konno R; Tanaka A; Suzuki M
Int J Gynecol Cancer; 2008; 18(1):165-7. PubMed ID: 17466052
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
25. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
26. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants.
Garg G; Kruger M; Christensen C; Deppe G; Toy EP
Int J Gynecol Cancer; 2011 Dec; 21(9):1606-12. PubMed ID: 21720252
[TBL] [Abstract][Full Text] [Related]
27. Neutrophilia and mortality in women with uterine carcinosarcoma.
Arend R; Van Arsdale A; Gojayev A; Roane BM; Doo D; Leath C; Goldberg GL; Huang G
Int J Gynecol Cancer; 2019 Oct; 29(8):1258-1263. PubMed ID: 31320488
[TBL] [Abstract][Full Text] [Related]
28. FIGO staging for carcinosarcoma: can the revised staging system predict overall survival?
Pradhan TS; Stevens EE; Ablavsky M; Salame G; Lee YC; Abulafia O
Gynecol Oncol; 2011 Nov; 123(2):221-4. PubMed ID: 21889193
[TBL] [Abstract][Full Text] [Related]
29. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
[TBL] [Abstract][Full Text] [Related]
30. Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G; Wabersich J; Ludwig K; Gardiman MP; Borgato L; Garbin F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):98-104. PubMed ID: 25468677
[TBL] [Abstract][Full Text] [Related]
31. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
Wu TI; Hsu KH; Huang HJ; Hsueh S; Chou HH; Tsai CS; Ho KC; Chao A; Chang TC; Lai CH
Eur J Gynaecol Oncol; 2008; 29(5):483-8. PubMed ID: 19051818
[TBL] [Abstract][Full Text] [Related]
33. Is Omentectomy Necessary for Non-Endometrioid Endometrial Cancer.
Kaban A; Topuz S; Erdem B; Sozen H; Numanoğlu C; Salihoğlu Y
Gynecol Obstet Invest; 2018; 83(5):482-486. PubMed ID: 28848103
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma.
Galaal K; Kew FM; Tam KF; Lopes A; Meirovitz M; Naik R; Godfrey KA; Hatem MH; Edmondson RJ
Eur J Obstet Gynecol Reprod Biol; 2009 Apr; 143(2):88-92. PubMed ID: 19201517
[TBL] [Abstract][Full Text] [Related]
35. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma.
Tanner EJ; Leitao MM; Garg K; Chi DS; Sonoda Y; Gardner GJ; Barakat RR; Jewell EL
Gynecol Oncol; 2011 Dec; 123(3):548-52. PubMed ID: 21945551
[TBL] [Abstract][Full Text] [Related]
36. Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma.
Inoue A; Yamaguchi K; Kurata Y; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Kido A; Konishi I; Matsumura N
J Gynecol Oncol; 2017 Sep; 28(5):e62. PubMed ID: 28657223
[TBL] [Abstract][Full Text] [Related]
37. Omental Micrometastasis in Endometrial Cancer.
Bayrak M; Yılmaz A; Yılmaz F; İlhan O; Oz Atalay F; Ozan H
Oncol Res Treat; 2019; 42(9):466-469. PubMed ID: 31340208
[TBL] [Abstract][Full Text] [Related]
38. Survival and risk factors associated with uterine sarcomas and carcinosarcomas in stage I and II.
Visnovsky J; Kudela E; Slavik P; Krkoska M; Buocik P; Szepe P; Danko J
Neuro Endocrinol Lett; 2015; 36(8):750-7. PubMed ID: 26921575
[TBL] [Abstract][Full Text] [Related]
39. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
40. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy.
Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM
Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]